^
Association details:
| Biomarker: | DCK exon 4 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Deoxycytidine Kinase (DCK) Mutations in Human Acute Myeloid Leukemia Resistant to Cytarabine
Published date:
02/24/2021
Excerpt:
We studied DCK mutations and messenger RNA (mRNA) concentrations in leukemia cells from 10 subjects with AML who received cytarabine-based therapy and relapsed and in 2 artificially induced cytarabine-resistant AML cell lines. DCK mutations were detected in 4 subjects with AML relapsing after achieving a complete remission and receiving high-dose cytarabine postremission therapy. Most mutations were in exons 4-6.
DOI:
10.1159/000513696
